In summary, we found that ROS1 mutations were uniquely present in GCB, while TET2 and TRAF3 were only present in non-GCB, and both MYD88 and CD79B mutations appeared only in DLBCL patients. This evidence concerns the gene TET2 and diffuse large B-cell lymphoma.